Other News

The Conformal Medical CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) System to be Prominently Featured at TCT 2024

Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk NASHUA, N.H., Oct. 22, 2024 /PRNewswire/ — Conformal Medical, Inc. announced today, the next-generation CLAAS® AcuFORM™ Left Atrial Appendage…

BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company’s common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant.

Gentuity® HF-OCT Imaging System Receives FDA 510(k) Clearance for Pre- and Post-Coronary Intervention Imaging

Intravascular Imaging Technology Featuring the World’s Smallest Imaging Catheter Now FDA Cleared for Pre- and Post-Intervention Use. SUDBURY, Mass., Oct. 22, 2024 /PRNewswire/ — Gentuity, LLC, a global leader in advanced intravascular imaging technologies, is pleased to announce that the…

Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA

NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here.

HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure

NANJING, China, Oct. 22, 2024 /PRNewswire/ — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes…

Arineta Expands Cardiac Care in Georgia with Installation of Advanced SpotLight™ Duo Scanner at PACE

New cardiac CT scanner enhances diagnostic capabilities and reduces wait times for patients across six Georgia locations Caesarea, Israel – Oct. 21, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions, announces the installation of its SpotLight™ Duo cardiac CT scanner at Peachstate Advanced Cardiac and Endovascular (PACE) in […]

Provident Healthcare Partners Advises Birmingham Heart Clinic in its Partnership with U.S. Heart & Vascular

BOSTON and NEW YORK, Oct. 21, 2024 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Birmingham Heart Clinic (“BHC”) in its partnership with U.S. Heart & Vascular (“USHV”). BHC is a provider of comprehensive…